SNY - Sanofi

NYSE - NYSE Delayed Price. Currency in USD
43.17
+0.08 (+0.19%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close43.09
Open43.14
Bid0.00 x 0
Ask0.00 x 0
Day's Range43.03 - 43.40
52 Week Range38.67 - 50.65
Volume1,748,901
Avg. Volume1,233,263
Market Cap107.854B
Beta0.78
PE Ratio (TTM)10.30
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.64 (3.81%)
Ex-Dividend Date2017-05-11
1y Target EstN/A
Trade prices are not sourced from all markets
  • Mylan Announces IPR Proceedings for Sanofi's Lantus Patents
    Zacksyesterday

    Mylan Announces IPR Proceedings for Sanofi's Lantus Patents

    Mylan (MYL) announced that interpartes review (IPR) proceedings has been initiated by PTAB regarding two Orange Book-listed patents, U.S. Patent Nos. 7,476,652 and 7,713,930 owned by Sanofi.

  • Alnylam Gets Some Welcome News
    Motley Foolyesterday

    Alnylam Gets Some Welcome News

    A trial that had been on clinical hold because of a patient death has been cleared to restart.

  • Beware: Price Wars For Big Pharma, Biotech Companies On Horizon
    Investor's Business Dailyyesterday

    Beware: Price Wars For Big Pharma, Biotech Companies On Horizon

    The FDA could further pressure generic drugmakers in 2018 by continuing along its path of increased generic approvals.

  • Investor's Business Dailyyesterday

    The FDA Just Blessed A Hemophilia Trial From This Biotech

    Alnylam edged up Friday after the FDA lifted its clinical hold on trials of a hemophilia drug, allowing Alnylam to start administering the drug before year-end.

  • Pharma Stock Roundup: Teva Announces Major Job Cuts, Lilly Provides 2018 Outlook
    Zacks2 days ago

    Pharma Stock Roundup: Teva Announces Major Job Cuts, Lilly Provides 2018 Outlook

    This week's pharma sector highlights include ASH data, Teva's restructuring announcement and Lilly's (LLY) 2018 outlook.

  • Sanofi Wants to Go It Alone -- Good Luck With That
    Bloomberg2 days ago

    Sanofi Wants to Go It Alone -- Good Luck With That

    The French drugmaker's in-house R&D efforts have been unimpressive.

  • Lilly Issues Guidance for 2018, New Drugs to Drive Top Line
    Zacks3 days ago

    Lilly Issues Guidance for 2018, New Drugs to Drive Top Line

    Eli Lilly (LLY) issues financial guidance for 2018 and also reaffirms the previously issued 2017 projection as well as its long-term expectations.

  • Will This Drug Kick-Start Regeneron Pharmaceuticals Shares?
    Motley Fool3 days ago

    Will This Drug Kick-Start Regeneron Pharmaceuticals Shares?

    An immuno-oncology drug that's in the works could generate significant revenue growth someday.

  • Regeneron, Sanofi Report Positive Top Line Skin Cancer Data
    Zacks3 days ago

    Regeneron, Sanofi Report Positive Top Line Skin Cancer Data

    Regeneron (REGN) and partner Sanofi announced positive top-line results from a pivotal phase II study of skin cancer candidate cemiplimab.

  • Top 10 Generic Pharmaceutical Companies In 2017
    Insider Monkey3 days ago

    Top 10 Generic Pharmaceutical Companies In 2017

    The top 10 generic pharmaceutical companies in 2017 operate in the relatively recession-proof pharmaceuticals industry which is immune from the vagaries of economic cycles. The huge R&D expense and expertise required to develop new medicines is a big entry barrier and the patent laws allow pharmaceuticals companies to make monopolistic profits for a new product […]

  • Reuters4 days ago

    France's Sanofi pins hopes on new drugs after setbacks

    Sanofi's (SASY.PA) promising pipeline of experimental drugs can help it overcome setbacks including the low uptake of a new cholesterol treatment and concerns about a dengue vaccine, the French pharmaceuticals group said on Wednesday. The world's sixth largest drugmaker, battling to contain the fallout from a safety row in the Philippines over dengue vaccine Dengvaxia, said it expected to file nine medicines for regulatory assessment in the next 18 months. Shares in Sanofi were down 0.77 percent at 1510 GMT.

  • Reuters4 days ago

    France's Sanofi pins hopes on new drugs after setbacks

    Sanofi's promising pipeline of experimental drugs can help it overcome setbacks including the low uptake of a new cholesterol treatment and concerns about a dengue vaccine, the French pharmaceuticals group said on Wednesday. The world's sixth largest drugmaker, battling to contain the fallout from a safety row in the Philippines over dengue vaccine Dengvaxia, said it expected to file nine medicines for regulatory assessment in the next 18 months. Shares in Sanofi were down 0.77 percent at 1510 GMT.

  • Reuters4 days ago

    Sanofi CEO says M&A targets in oncology are 'very expensive'

    PARIS (Reuters) - Sanofi's Chief Executive Olivier Brandicourt on Wednesday told investors that he considered M&A targets in oncology to be "very expensive". "If you are not starting with ...

  • Reuters4 days ago

    Did Sanofi, WHO ignore warning signals on dengue vaccine?

    CHICAGO/LONDON (Reuters) - When French drugmaker Sanofi published the results of clinical trials of children given its dengue vaccine two years ago, the overall findings were that it protected against the world's biggest and fastest growing mosquito-borne disease. The study's authors cited two main possibilities: the children had immature immune systems that made the vaccine less protective, or the vaccine itself made them more susceptible to severe disease if they had never had dengue and later became infected. More than two years later, it turns out the latter was the primary factor - a revelation at the end of last month that has triggered alarm among hundreds of thousands of anxious parents in the Philippines, where the vaccine has been given to over 830,000 children.

  • Reuters4 days ago

    Did Sanofi, WHO ignore warning signals on dengue vaccine?

    CHICAGO/LONDON, Dec 12 (Reuters) - When French drugmaker Sanofi published the results of clinical trials of children given its dengue vaccine two years ago, the overall findings were that it protected against the world's biggest and fastest growing mosquito-borne disease. The study's authors cited two main possibilities: the children had immature immune systems that made the vaccine less protective, or the vaccine itself made them more susceptible to severe disease if they had never had dengue and later became infected. More than two years later, it turns out the latter was the primary factor - a revelation at the end of last month that has triggered alarm among hundreds of thousands of anxious parents in the Philippines, where the vaccine has been given to over 830,000 children.

  • TheStreet.com5 days ago

    Dengue Fever Vaccine Suspension Criticized by Drugmaker Sanofi

    French drug-maker Sanofi contends its Dengue vaccine is good for the country. After 730,000 children were vaccinated, the Philippine government stopped the program on data the drug-maker released that ...

  • Sanofi Wins FDA Approval for Biosimilar of Lilly's Humalog
    Zacks5 days ago

    Sanofi Wins FDA Approval for Biosimilar of Lilly's Humalog

    Sanofi's (SNY) Admelog, a follow-on biologic version of Lilly's Humalog, received FDA approval.

  • Reuters5 days ago

    Sanofi investors hungry for drug progress and deal news

    Sanofi (SASY.PA) still needs to convince markets it can deliver on an exciting and sustainable growth path as it contends with fresh difficulties in its vaccines arm and looks set for another gloomy year in diabetes, investors told Reuters. The French drugmaker holds an "innovation day" on Wednesday to discuss its pipeline of new drugs while it attempts to overcome fallout from a safety row in the Philippines over its dengue vaccine. Shares in Sanofi are trading close to a 10-month low and are down more than 4 percent this year after a 2.2 percent decline last year.

  • Reuters5 days ago

    Sanofi investors hungry for drug progress and deal news

    Sanofi still needs to convince markets it can deliver on an exciting and sustainable growth path as it contends with fresh difficulties in its vaccines arm and looks set for another gloomy year in diabetes, investors told Reuters. The French drugmaker holds an "innovation day" on Wednesday to discuss its pipeline of new drugs while it attempts to overcome fallout from a safety row in the Philippines over its dengue vaccine. Shares in Sanofi are trading close to a 10-month low and are down more than 4 percent this year after a 2.2 percent decline last year.

  • Reuters5 days ago

    FDA OKs Sanofi's follow-on biologic of Lilly's diabetes drug Humalog

    The U.S. Food and Drug Administration said on Monday it approved Sanofi SA's Admelog as the first follow-on biologic version of Eli Lilly and Co's fast-acting insulin, Humalog. Admelog, generally taken just before meals, was approved for use in children older than three and adults with type 1 diabetes, as well as adults with type 2 diabetes. Like Humalog, which earned Lilly $696.2 million in the latest quarter, the short-acting drug helps diabetics control blood sugar levels after eating.

  • Reuters5 days ago

    FDA clears Sanofi's follow-on diabetes biologic of Lilly's Humalog

    The U.S. Food and Drug Administration said on Monday it approved Sanofi SA's Admelog as the first follow-on biologic version of Eli Lilly and Co's fast-acting insulin, Humalog. The drug is a short-acting ...

  • 3 High-Yield Dividend Stocks to Buy in 2018
    Motley Fool6 days ago

    3 High-Yield Dividend Stocks to Buy in 2018

    These 3 Big Pharma stocks may be worth adding to your portfolio in 2018.

  • Regeneron (REGN) Down 8.3% Since Earnings Report: Can It Rebound?
    Zacks6 days ago

    Regeneron (REGN) Down 8.3% Since Earnings Report: Can It Rebound?

    Regeneron (REGN) reported earnings more than 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Sanofi Begins Combo Studies on Multiple Myeloma Candidate
    Zacks9 days ago

    Sanofi Begins Combo Studies on Multiple Myeloma Candidate

    Sanofi (SNY) starts two new phase III studies evaluating isatuximab in combination with other cancer medicines for the treatment of multiple myeloma, a rare blood cancer.

  • Market Realist9 days ago

    How Eli Lilly’s Trajenta, Trulicity, and Basaglar Are Performing

    In 3Q17, Eli Lilly's (LLY) Trajenta generated revenues of $153.3 million, ~33% growth on a year-over-year (or YoY) basis and ~8% growth on a quarter-over-quarter basis.